Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
TB-500 administration: Subcutaneous injection
The standard therapeutic dose is 0.51.0mL subcutaneously once weekly, injected into the lower abdomen or lateral thigh with a 25G or 27G needle
Acronyms A1C - Hemoglobin A1C ADA - American Diabetes Association CVD - Cardiovascular disease DM - Diabetes mellitus FBS - Fasting blood sugar GFR - Glomerular filtration rate GI - Gastrointestinal GLP-1 - Glucagon-like peptide-1 OSA - Obstructive sleep apnea RCT - Randomized controlled trial T2DM - Type 2 diabetes mellitus Thyroid C-cell tumor = Thyroid medullary tumor DRUGS IN CLASS Dual GLP-1 and GIP agonists Tirzepatide (Mounjaro) - marketed for diabetes Tirzepatide (Zepbound) - marketed for weight loss MECHANISM OF ACTION GLP-1 and GIP GLP-1 stands for "glucagon-like peptide-1," and GIP stands for "glucose-dependent insulinotropic polypeptide." GIP is also sometimes referred to as "gastric inhibitory polypeptide." GLP-1 and GIP are hormones secreted by specialized cells in the small intestine in response to food consumption
As well as side effects and possible health damage from the hormone itself, users could be putting themselves at risk of injecting harmful bacteria into their system
Cloning and characterization of a glutathione S-transferase that can be photolabelled with 5-azido-indole-3-acetic acid
